Michael I. Nishimura

9.6k total citations · 1 hit paper
135 papers, 6.5k citations indexed

About

Michael I. Nishimura is a scholar working on Immunology, Oncology and Molecular Biology. According to data from OpenAlex, Michael I. Nishimura has authored 135 papers receiving a total of 6.5k indexed citations (citations by other indexed papers that have themselves been cited), including 101 papers in Immunology, 75 papers in Oncology and 28 papers in Molecular Biology. Recurrent topics in Michael I. Nishimura's work include Immunotherapy and Immune Responses (67 papers), CAR-T cell therapy research (67 papers) and T-cell and B-cell Immunology (50 papers). Michael I. Nishimura is often cited by papers focused on Immunotherapy and Immune Responses (67 papers), CAR-T cell therapy research (67 papers) and T-cell and B-cell Immunology (50 papers). Michael I. Nishimura collaborates with scholars based in United States, Netherlands and Japan. Michael I. Nishimura's co-authors include Elizabeth Garrett‐Mayer, David J. Cole, Mohamed L. Salem, C. Marcela Díaz‐Montero, Alberto J. Montero, Steven A. Rosenberg, Timothy M. Clay, Mary Custer, Suzanne L. Topalian and S A Rosenberg and has published in prestigious journals such as Science, Proceedings of the National Academy of Sciences and Journal of Clinical Investigation.

In The Last Decade

Michael I. Nishimura

134 papers receiving 6.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin–cyclophosphamide chemotherapy

2008 992 citations Mohamed L. Salem, Michael I. Nishimura et al. Cancer Immunology Immunotherapy profile →

Peers

Countries citing papers authored by Michael I. Nishimura

Since Specialization

Citations

This map shows the geographic impact of Michael I. Nishimura's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael I. Nishimura with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael I. Nishimura more than expected).

Fields of papers citing papers by Michael I. Nishimura

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael I. Nishimura. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael I. Nishimura. The network helps show where Michael I. Nishimura may publish in the future.

Co-authorship network of co-authors of Michael I. Nishimura

This figure shows the co-authorship network connecting the top 25 collaborators of Michael I. Nishimura. A scholar is included among the top collaborators of Michael I. Nishimura based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael I. Nishimura. Michael I. Nishimura is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Targeting protein tyrosine phosphatases for CDK6-induced immunotherapy resistance 2023 ·Cell Reports ·Xueliang Gao, Yongxia Wu, Joel M. Chick, Andrea M. Abbott, Baishan Jiang, Jingxin Wang, Susana Comte‐Walters, Roger H. Johnson, (unknown), Michael I. Nishimura, Steven P. Gygi, Anand S. Mehta, Denis C. Guttridge, Lauren E. Ball, (unknown), Piotr Siciński, Xue‐Zhong Yu, (unknown)	6
2	Lifetimes of Punishment: The Imperial Feedback Loop of Anti‐Asian Violence 2023 ·Sociological Inquiry ·Michael I. Nishimura	0
3	Siglec‐5 is an inhibitory immune checkpoint molecule for human T cells 2022 ·Immunology ·(unknown), (unknown), Gina Scurti, Michael I. Nishimura, Paula White, Andrew T. Ulijasz, Makio Iwashima	45
4	A class-mismatched TCR bypasses MHC restriction via an unorthodox but fully functional binding geometry 2022 ·Nature Communications ·Nishant K. Singh, Jesus A. Alonso, Jason R. Devlin, Grant L. J. Keller, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Lance M. Hellman, Michael I. Nishimura, Brian M. Baker	8
5	Identification of human CD4 ⁺ T cell populations with distinct antitumor activity 2020 ·Science Advances ·Michelle H. Nelson, Hannah M. Knochelmann, Stefanie R. Bailey, (unknown), Jacob S. Bowers, Kinga Majchrzak, Megan M. Wyatt, Mark P. Rubinstein, Shikhar Mehrotra, Michael I. Nishimura, Kent Armeson, Paul G. Giresi, Michael J. Zilliox, Hal E. Broxmeyer, Chrystal M. Paulos	31
6	Identification of human CD4+ T cell populations with distinct antitumor activity 2020 ·PMC ·Michelle H. Nelson, Hannah M. Knochelmann, Stefanie R. Bailey, (unknown), Jacob S. Bowers, Kinga Majchrzak, Megan M. Wyatt, Mark P. Rubinstein, Shikhar Mehrotra, Michael I. Nishimura, Kent Armeson, Paul G. Giresi, Michael J. Zilliox, Hal E. Broxmeyer, Chrystal M. Paulos	1
7	Late Events After CD-19 CAR-T Treatment 2019 ·Biology of Blood and Marrow Transplantation ·Nasheed Hossain, Michael I. Nishimura	2
8	N-acetyl cysteine protects anti-melanoma cytotoxic T cells from exhaustion induced by rapid expansion via the downmodulation of Foxo1 in an Akt-dependent manner 2018 ·Cancer Immunology Immunotherapy ·(unknown), Gina Scurti, Megan M. Wyatt, Elizabeth Garrett‐Mayer, Chrystal M. Paulos, Michael I. Nishimura, Christina Voelkel‐Johnson	38
9	Efficacy of Adoptive T-cell Therapy Is Improved by Treatment with the Antioxidant N-Acetyl Cysteine, Which Limits Activation-Induced T-cell Death 2016 ·Cancer Research ·(unknown), Gina Scurti, Patricia Simms, Elizabeth Garrett‐Mayer, Shikhar Mehrotra, Michael I. Nishimura, Christina Voelkel‐Johnson	58
10	Feasibility of Telomerase-Specific Adoptive T-cell Therapy for B-cell Chronic Lymphocytic Leukemia and Solid Malignancies 2016 ·Cancer Research ·(unknown), Sara Bobisse, (unknown), Alessia Lamolinara, Francesco De Sanctis, Federico Boschi, Andrea Sbarbati, Giulio Fracasso, (unknown), Rudi W. Hendriks, Chiara Cavallini, Maria Teresa Scupoli, Silvia Sartoris, Manuela Iezzi, Michael I. Nishimura, Vincenzo Bronte, Stefano Ugel	25
11	Promoting Thiol Expression Increases the Durability of Antitumor T-cell Functions 2014 ·Cancer Research ·Pravin Kesarwani, Amir A. Al-Khami, Gina Scurti, (unknown), (unknown), Shahid Husain, Quan Fang, Osama Naga, Patricia Simms, Gyda Beeson, Christina Voelkel‐Johnson, Elizabeth Garrett‐Mayer, Craig C. Beeson, Michael I. Nishimura, Shikhar Mehrotra	39
12	Off-Target Function of the Sonic Hedgehog Inhibitor Cyclopamine in Mediating Apoptosis via Nitric Oxide–Dependent Neutral Sphingomyelinase 2/Ceramide Induction 2012 ·Molecular Cancer Therapeutics ·Marisa Meyers‐Needham, (unknown), Salih Gencer, R. David Sentelle, Sahar A. Saddoughi, Christopher J. Clarke, Yusuf A. Hannun, Håkan Norell, Telma Martins da Palma, Michael I. Nishimura, Jacqueline M. Kraveka, Zohreh Khavandgar, Monzur Murshed, (unknown), Besim Öğretmen	33
13	Kinetic phases of distribution and tumor targeting by T cell receptor engineered lymphocytes inducing robust antitumor responses 2010 ·Proceedings of the National Academy of Sciences ·Richard C. Koya, Stephen Mok, Begoña Comı́n-Anduix, Thinle Chodon, Caius G. Radu, Michael I. Nishimura, Owen N. Witte, Antoni Ribas	48
14	Tim-3 expression on PD-1+ HCV-specific human CTLs is associated with viral persistence, and its blockade restores hepatocyte-directed in vitro cytotoxicity 2010 ·Journal of Clinical Investigation ·Rachel H. McMahan, Lucy Golden‐Mason, Michael I. Nishimura, Brian J. McMahon, Michael Kemper, Todd M. Allen, David R. Gretch, Hugo R. Rosen	253
15	Melanoma-Associated Antigen Expression in Lymphangioleiomyomatosis Renders Tumor Cells Susceptible to Cytotoxic T Cells 2009 ·American Journal Of Pathology ·Jared Klarquist, (unknown), Sridhar Kandala, (unknown), R. Braun, (unknown), Daniel F. Dilling, Mark D. McKee, Raymond E. Boissy, Robert B. Love, Michael I. Nishimura, I. Caroline Le Poole	26
16	Recognition of Host Immune Activation by Pseudomonas aeruginosa 2005 ·Science ·Licheng Wu, Oscar Estrada, Olga Zaborina, Manjeet Bains, Le Shen, Jonathan E. Kohler, Nachiket Patel, Mark W. Musch, Eugene B. Chang, Yang‐Xin Fu, Michael A. Jacobs, Michael I. Nishimura, Robert E. W. Hancock, Jerrold R. Turner, John C. Alverdy	256
17	Interferon-γ renders tumors that express low levels of Her-2/neu sensitive to cytotoxic T cells 2005 ·Cancer Immunology Immunotherapy ·Barbara L.F. Kaplan, Håkan Norell, Glenda G. Callender, (unknown), Rolf Kiessling, Michael I. Nishimura	8
18	Cutting Edge: The NK Cell Receptor 2B4 Augments Antigen-Specific T Cell Cytotoxicity Through CD48 Ligation on Neighboring T Cells 2003 ·The Journal of Immunology ·Kyung‐Mi Lee, (unknown), Takashi Majima, Hairong Wei, Michael I. Nishimura, Hideo Yagita∥, Vinay Kumar	72
19	Transfer of TCR Genes into Mature T Cells Is Accompanied by the Maintenance of Parental T Cell Avidity 2003 ·The Journal of Immunology ·Mark P. Rubinstein, Andre N. Kadima, Mohamed L. Salem, Christophe Nguyen, William E. Gillanders, Michael I. Nishimura, David J. Cole	42
20	CD8-Independent Tumor Cell Recognition Is a Property of the T Cell Receptor and Not the T Cell 2003 ·The Journal of Immunology ·J. Roszkowski, David C. Yu, Mark P. Rubinstein, Mark D. McKee, David J. Cole, Michael I. Nishimura	46

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact